Mie, T.; Sasaki, T.; Takeda, T.; Okamoto, T.; Hamada, T.; Ishitsuka, T.; Yamada, M.; Nakagawa, H.; Furukawa, T.; Kasuga, A.;
et al. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 2023, 15, 358.
https://doi.org/10.3390/cancers15020358
AMA Style
Mie T, Sasaki T, Takeda T, Okamoto T, Hamada T, Ishitsuka T, Yamada M, Nakagawa H, Furukawa T, Kasuga A,
et al. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers. 2023; 15(2):358.
https://doi.org/10.3390/cancers15020358
Chicago/Turabian Style
Mie, Takafumi, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga,
and et al. 2023. "Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer" Cancers 15, no. 2: 358.
https://doi.org/10.3390/cancers15020358
APA Style
Mie, T., Sasaki, T., Takeda, T., Okamoto, T., Hamada, T., Ishitsuka, T., Yamada, M., Nakagawa, H., Furukawa, T., Kasuga, A., Matsuyama, M., Ozaka, M., & Sasahira, N.
(2023). Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers, 15(2), 358.
https://doi.org/10.3390/cancers15020358
